ASCO 2019 | DUO trial: duvelisib for CLL/SLL

Ian Flinn

Ian Flinn, MD, PhD, from Tennessee Oncology, Nashville, TN, delivers an update on the DUO trial (NCT02004522) looking at duvelisib for R/R chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and how PI3K inhibitors will be used in CLL therapy going forward. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics